[PDF][PDF] Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
LR Silverman, DR McKenzie, BL Peterson, JF Holland… - J Clin Oncol, 2006 - academia.edu
LR Silverman, DR McKenzie, BL Peterson, JF Holland, JT Backstrom, CL Beach, RA Larson
J Clin Oncol, 2006•academia.eduPurpose Within the last two decades, a new understanding of the biology of myelodysplastic
syndrome (MDS) has developed. With this understanding, new classification systems, such
as the WHO diagnostic criteria, and the International Prognostic Scoring System and
response criteria guidelines reported by the International Working Group (IWG) have been
developed. We report the combined results of three previously reported clinical trials (n 309)
with azacitidine using the WHO classification system for MDS and acute myeloid leukemia …
syndrome (MDS) has developed. With this understanding, new classification systems, such
as the WHO diagnostic criteria, and the International Prognostic Scoring System and
response criteria guidelines reported by the International Working Group (IWG) have been
developed. We report the combined results of three previously reported clinical trials (n 309)
with azacitidine using the WHO classification system for MDS and acute myeloid leukemia …
Purpose
Within the last two decades, a new understanding of the biology of myelodysplastic syndrome (MDS) has developed. With this understanding, new classification systems, such as the WHO diagnostic criteria, and the International Prognostic Scoring System and response criteria guidelines reported by the International Working Group (IWG) have been developed. We report the combined results of three previously reported clinical trials (n 309) with azacitidine using the WHO classification system for MDS and acute myeloid leukemia (AML) and IWG criteria for response.
academia.edu
